Aspire Biopharma Holdings
ASBPAspire Biopharma is an early-stage biopharmaceutical company focused on developing and commercializing a proprietary sublingual delivery platform for drugs and nutraceuticals.
Earnings
Next report
Date not yet announcedCompetitors
By market cap
By revenue growth
Profile
Aspire Biopharma is an early-stage biopharmaceutical company focused on developing and commercializing a proprietary sublingual delivery platform for drugs and nutraceuticals. The company's technology utilizes a patent-pending formulation and trade secret process to enable rapid absorption through the oral mucosa, bypassing the gastrointestinal tract to improve onset time and reduce toxicity. Their primary strategy involves reformulating established compounds into fast-acting, pH-neutral powders or granules for emergency and specialty care applications.
An early-stage innovator in sublingual drug delivery seeking to disrupt traditional oral administration for acute myocardial infarction and pain management.
FAQ
- What is Aspire Biopharma Holdings's market cap?
- Aspire Biopharma Holdings (ASBP) has a market capitalization of $12.0M and trades on NASDAQ.
- Who are Aspire Biopharma Holdings's competitors?
- Aspire Biopharma Holdings's key competitors include Johnson & Johnson, Amphastar Pharmaceuticals, Inc., Nutriband Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Aspire Biopharma Holdings partner with?
- Aspire Biopharma Holdings's notable partners include Glatt, Microsize, Desert Stream, Inc., and others.
- What subsidiaries does Aspire Biopharma Holdings have?
- Aspire Biopharma Holdings's subsidiaries include Buzz Bomb Caffeine Company LC, Aspire Biopharma, Inc..
- Where is Aspire Biopharma Holdings headquartered?
- Aspire Biopharma Holdings is headquartered in United States of America. It has been publicly traded since 2025.